How Do You Use the DecisionDx®-Melanoma Test Results?

DecisionDx®-Melanoma provides you and your healthcare professional with personalized information to help inform decisions about your follow-up management and care plan and sentinel lymph node biopsy (SLNB) surgical procedure. The test identifies the likelihood that your tumor could recur or spread within the next 5 years. For most patients eligible for a SLNB, the test can also provide information to help make decisions about this surgical procedure.

When your results are ready, your provider will receive a personalized report to share with you:

CM-Final-Report-Template_2021
CM-ITR-Web-Content

Your tumor will be classified into a risk group:

Class

1A

LOWEST RISK

Class 1A signature is associated with the lowest risk of recurrence within 5 years.


In patients 55 years and older with T1-T2 tumors, a Class 1 A result is associated with low probability of a positive sentinel lymph node.




Class

1B/2A

INCREASED RISK

Class 1B/2A molecular signature is associated with an increased risk of recurrence within 5 years relative to Class 1A





Class

2B

HIGHEST RISK

Class 2B signature is associated with the highest risk of recurrence within 5 years relative to Class 1.


In patients with T1-T2 tumors, a Class 2B result is associated with a higher probability of a positive sentinel lymph node.



Integrated Test Result: Once your DecisionDx-Melanoma Class result is determined, it will be incorporated with your clinical and pathological risk factors (Breslow thickness, ulceration, mitotic rate,age,SLN status, and tumor location) to provide precise and personalized predictions for the risk of your cancer coming back and likelihood of sentinel lymph node positivity.

These individualized test results can help you and your healthcare professional make decisions about your treatment, follow-up appointments, referrals and the SLNB surgical procedure. Typically SLNB should be discussed and considered when a patient’s risk of positivity is greater than 10%. For those with risk between 5% and 10%, SLNB is sometimes considered. For those with risk less than 5%, SLNB is generally not recommended.

Learn How
DecisionDx®-Melanoma
Can Predict the Risk of Your Melanoma Recurring or Spreading

DecisionDXMelanomaColor.svg
Learn More

Download the Healthcare Professional Discussion Guide

MySkinMel-DiscussionGuide.png

What’s Next?

Is DecisionDx-Melanoma Covered by Insurance?

LEARN MORE

How Do You Get a
DecisionDx-Melanoma Test?

LEARN MORE